Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

L. Pour, M. Szarejko, J. Bila, FH. Schjesvold, I. Spicka, V. Maisnar, A. Jurczyszyn, Z. Grudeva-Popova, R. Hájek, G. Usenko, M. Thuresson, S. Norin, S. Jarefors, NA. Bakker, PG. Richardson, MV. Mateos

. 2024 ; 109 (3) : 895-905. [pub] 20240301

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007007

Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM with disease refractory to an immunomodulatory agent and a proteasome inhibitor or who had received ≥3 prior lines of therapy including an immunomodulatory agent and a proteasome inhibitor. A partial clinical hold issued by the US Food and Drug Administration for all melflufen studies led to financial constraints and premature study closure on February 23rd 2022 (data cut-off date). In total, 54 of 240 planned patients were randomized (melflufen group, N=27; daratumumab group, N=27). Median progression-free survival (PFS) was not reached in the melflufen group versus 4.9 months in the daratumumab group (Hazard Ratio: 0.18 [95% Confidence Interval, 0.05-0.65]; P=0.0032) at a median follow-up time of 7.1 and 6.6 months, respectively. Overall response rate (ORR) was 59% in the melflufen group versus 30% in the daratumumab group (P=0.0300). The most common grade ≥3 treatment-emergent adverse events in the melflufen group versus daratumumab group were neutropenia (50% vs. 12%), thrombocytopenia (50% vs. 8%), and anemia (32% vs. 19%). Melflufen plus daratumumab and dexamethasone demonstrated superior PFS and ORR versus daratumumab in RRMM and a safety profile comparable to previously published melflufen studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007007
003      
CZ-PrNML
005      
20240423155642.0
007      
ta
008      
240412s2024 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2023.283509 $2 doi
035    __
$a (PubMed)37646660
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Pour, Luděk $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic. pour.ludek@fnbrno.cz
245    10
$a Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study / $c L. Pour, M. Szarejko, J. Bila, FH. Schjesvold, I. Spicka, V. Maisnar, A. Jurczyszyn, Z. Grudeva-Popova, R. Hájek, G. Usenko, M. Thuresson, S. Norin, S. Jarefors, NA. Bakker, PG. Richardson, MV. Mateos
520    9_
$a Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM with disease refractory to an immunomodulatory agent and a proteasome inhibitor or who had received ≥3 prior lines of therapy including an immunomodulatory agent and a proteasome inhibitor. A partial clinical hold issued by the US Food and Drug Administration for all melflufen studies led to financial constraints and premature study closure on February 23rd 2022 (data cut-off date). In total, 54 of 240 planned patients were randomized (melflufen group, N=27; daratumumab group, N=27). Median progression-free survival (PFS) was not reached in the melflufen group versus 4.9 months in the daratumumab group (Hazard Ratio: 0.18 [95% Confidence Interval, 0.05-0.65]; P=0.0032) at a median follow-up time of 7.1 and 6.6 months, respectively. Overall response rate (ORR) was 59% in the melflufen group versus 30% in the daratumumab group (P=0.0300). The most common grade ≥3 treatment-emergent adverse events in the melflufen group versus daratumumab group were neutropenia (50% vs. 12%), thrombocytopenia (50% vs. 8%), and anemia (32% vs. 19%). Melflufen plus daratumumab and dexamethasone demonstrated superior PFS and ORR versus daratumumab in RRMM and a safety profile comparable to previously published melflufen studies.
650    _2
$a lidé $7 D006801
650    12
$a monoklonální protilátky $7 D000911
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    12
$a melfalan $x analogy a deriváty $7 D008558
650    12
$a mnohočetný myelom $x diagnóza $x farmakoterapie $7 D009101
650    12
$a nádory plazmocelulární $7 D054219
650    12
$a neutropenie $7 D009503
650    12
$a fenylalanin $x analogy a deriváty $7 D010649
650    _2
$a inhibitory proteasomu $7 D061988
650    _2
$a autologní transplantace $7 D014182
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Szarejko, Monika $u University Clinical Centre, Department of Hematology and Transplantology, Gdansk
700    1_
$a Bila, Jelena $u Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade
700    1_
$a Schjesvold, Fredrik H $u Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo
700    1_
$a Spicka, Ivan $u 1<sup>st</sup> Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
700    1_
$a Maisnar, Vladimir $u 4<sup>th</sup> Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
700    1_
$a Jurczyszyn, Artur $u Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Faculty of Medicine, Krakow
700    1_
$a Grudeva-Popova, Zhanet $u Department of Clinical Oncology, Medical Faculty, Medical University of Plovdiv, Plovdic, Bulgaria
700    1_
$a Hájek, Roman $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Usenko, Ganna $u City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine
700    1_
$a Thuresson, Marcus $u Oncopeptides AB, Stockholm
700    1_
$a Norin, Stefan $u Oncopeptides AB, Stockholm
700    1_
$a Jarefors, Sara $u Oncopeptides AB, Stockholm
700    1_
$a Bakker, Nicolaas A $u Oncopeptides AB, Stockholm
700    1_
$a Richardson, Paul G $u Dana-Farber Cancer Institute, Boston, MA
700    1_
$a Mateos, Maria-Victoria $u Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 109, č. 3 (2024), s. 895-905
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37646660 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155639 $b ABA008
999    __
$a ok $b bmc $g 2081169 $s 1216774
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 109 $c 3 $d 895-905 $e 20240301 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace